NCT00728000 2019-11-25
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Withdrawn
University of Cincinnati
Dana-Farber Cancer Institute
University of California, San Francisco